- Conditions
- Lung Cancer
- Interventions
- carboplatin, paclitaxel, three-dimensional conformal radiation therapy
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- Not listed
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2013
- U.S. locations
- 40
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Burbank, California + 30 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1825–1848
of 5,286
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cirrhosis, Liver, Transjugular Intrahepatic Portosystemic Shunt (TIPS)
- Interventions
- Not listed
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 852 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Redwood City, California • San Diego, California + 8 more
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Tumor, Ovarian Seromucinous Carcinoma, Ovarian Serous Tumor, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Carcinoma
- Interventions
- Biospecimen Collection, Carboplatin, Cediranib Maleate, Computed Tomography, Echocardiography Test, Gemcitabine, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Pharmacological Study, Quality-of-Life Assessment
- Procedure · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 579 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 337
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 256 more
- Conditions
- Phenylketonuria
- Interventions
- Sapropterin dihydrochloride, Placebo
- Drug
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 8 Years to 65 Years
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 26
- States / cities
- La Jolla, California • Los Angeles, California • Palo Alto, California + 23 more
- Conditions
- Adenovirus Infection
- Interventions
- Posoleucel, Placebo
- Drug
- Lead sponsor
- AlloVir
- Industry
- Eligibility
- Not listed
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 23
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 19 more
- Conditions
- Healthy
- Interventions
- Mannooligosaccharides yeast extract
- Dietary Supplement
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 50 Years to 99 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Chronic Hepatitis C Virus
- Interventions
- LDV/SOF, RBV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 870 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 53
- States / cities
- Birmingham, Alabama • La Jolla, California • Long Beach, California + 50 more
- Conditions
- Myelodysplastic Syndromes (MDS)
- Interventions
- Panobinostat
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 7
- States / cities
- Fort Myers, Florida • Gainesville, Georgia • Louisville, Kentucky + 4 more
- Conditions
- Myotonic Dystrophy Type 1, DM1, Myotonic Dystrophy, Myotonia, Myotonic Dystrophy 1, Myotonic Disorders, Steinert Myotonic Dystrophy, Steinert Disease
- Interventions
- Del-desiran (AOC 1001)
- Drug
- Lead sponsor
- Avidity Biosciences, Inc.
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 19
- States / cities
- Los Angeles, California • Stanford, California • Denver, Colorado + 16 more
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Interventions
- Cediranib, Cediranib Maleate, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Questionnaire Administration, Topotecan, Topotecan Hydrochloride
- Drug · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 582 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 370
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 285 more
- Conditions
- Friedreich Ataxia
- Interventions
- Spinal tap for CSF collection, Venipuncture for blood sample
- Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Bladder Cancer
- Interventions
- Hexvix, Standard white light cystoscopy
- Drug · Procedure
- Lead sponsor
- Photocure
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 789 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 15
- States / cities
- Stanford, California • Gainesville, Florida • Miami, Florida + 12 more
- Conditions
- Age-related Cognitive Decline, Alzheimer's Disease and Related Dementias
- Interventions
- Cognitive Training, Computerized Cognitive Stimulation
- Behavioral
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 7,600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2028
- U.S. locations
- 7
- States / cities
- Gainesville, Florida • Jacksonville, Florida • Sarasota, Florida + 3 more
- Conditions
- Myelodysplastic Syndromes
- Interventions
- Omacetaxine, Azacitidine, G-CSF
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- AC2993
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 16 Years to 75 Years
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 219
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Eclectic, Alabama + 162 more
- Conditions
- Obstructive Sleep Apnea
- Interventions
- Auto AFlex, Auto CPAP, CPAP
- Device
- Lead sponsor
- Philips Respironics
- Industry
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 168 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Stanford, California • New Haven, Connecticut + 1 more
- Conditions
- Staphylococcal Infections, Surgical Site Infection
- Interventions
- XF-73, Placebo
- Drug
- Lead sponsor
- Destiny Pharma Plc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 7
- States / cities
- Gainesville, Florida • Pocatello, Idaho • Des Moines, Iowa + 4 more
- Conditions
- Total Knee Arthroplasty (TKA)
- Interventions
- Home Strengthening Exercises, Standard Physical Therapy, Preoperative Assessments
- Behavioral · Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 4
- States / cities
- Gainesville, Florida
- Conditions
- Burns
- Interventions
- Enteral Glutamine, Placebo
- Dietary Supplement
- Lead sponsor
- Daren K. Heyland
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2021
- U.S. locations
- 27
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 24 more
- Conditions
- Partial Edentulism
- Interventions
- all-ceramic fixed partial denture
- Device
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1998 – 2004
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Substance Use, HIV/AIDS, Older Adults, Behavioral Intervention, Infectious Disease
- Interventions
- Psycho-educational content (5 Minutes), Readiness Assessment (10 minutes), Goal-Setting (5 minutes), Identifying and prioritizing needs (5 minutes), Explanation of Peer Navigator and Session wrap (5 minutes)
- Behavioral
- Lead sponsor
- Florida State University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 3
- States / cities
- Gainesville, Florida • Jacksonville, Florida • Lake City, Florida
- Conditions
- Childhood Extracranial Germ Cell Tumor, Extragonadal Embryonal Carcinoma, Germ Cell Tumor, Malignant Germ Cell Tumor, Malignant Ovarian Teratoma, Stage I Ovarian Choriocarcinoma, Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7, Stage I Testicular Choriocarcinoma AJCC v6 and v7, Stage I Testicular Embryonal Carcinoma AJCC v6 and v7, Stage I Testicular Seminoma AJCC v6 and v7, Stage I Testicular Yolk Sac Tumor AJCC v6 and v7, Stage II Ovarian Choriocarcinoma, Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7, Stage II Testicular Choriocarcinoma AJCC v6 and v7, Stage II Testicular Embryonal Carcinoma AJCC v6 and v7, Stage II Testicular Yolk Sac Tumor AJCC v6 and v7, Stage III Ovarian Choriocarcinoma, Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7, Stage III Testicular Choriocarcinoma AJCC v6 and v7, Stage III Testicular Embryonal Carcinoma AJCC v6 and v7, Stage III Testicular Yolk Sac Tumor AJCC v6 and v7, Stage IV Ovarian Choriocarcinoma, Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7, Testicular Mixed Choriocarcinoma and Embryonal Carcinoma, Testicular Mixed Choriocarcinoma and Teratoma, Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
- Interventions
- Best Practice, Biopsy Procedure, Biospecimen Collection, Bleomycin Sulfate, Carboplatin, Cisplatin, Computed Tomography, Etoposide, Magnetic Resonance Imaging, Pulmonary Function Test, Questionnaire Administration
- Other · Procedure · Biological + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Not listed
- Enrollment
- 1,780 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 566
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 338 more
- Conditions
- Irritable Bowel Syndrome With Diarrhea (IBS-D)
- Interventions
- DNK333, Placebo
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 180 participants
- Timeline
- 2006 – 2007
- U.S. locations
- 37
- States / cities
- Tucson, Arizona • North Little Rock, Arkansas • Los Angeles, California + 34 more
- Conditions
- Heart Decompensation
- Interventions
- Nesiritide, Placebo
- Drug
- Lead sponsor
- Scios, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7,141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 171
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Anchorage, Alaska + 168 more